• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Sci Rep . Prediction of disease progression in patients with COVID-19 by artificial intelligence assisted lesion quantification

tetano

Editor, Senior Moderator
Sci Rep


. 2020 Dec 16;10(1):22083.
doi: 10.1038/s41598-020-79097-1.
Prediction of disease progression in patients with COVID-19 by artificial intelligence assisted lesion quantification


Yuehua Li[SUP] 1 [/SUP], Kai Shang[SUP] 1 [/SUP], Wei Bian[SUP] 2 [/SUP], Li He[SUP] 3 [/SUP], Ying Fan[SUP] 2 [/SUP], Tao Ren[SUP] 3 [/SUP], Jiayin Zhang[SUP] 4 [/SUP]



Affiliations

Abstract

To investigate the value of artificial intelligence (AI) assisted quantification on initial chest CT for prediction of disease progression and clinical outcome in patients with coronavirus disease 2019 (COVID-19). Patients with confirmed COVID-19 infection and initially of non-severe type were retrospectively included. The initial CT scan on admission was used for imaging analysis. The presence of ground glass opacity (GGO), consolidation and other findings were visually evaluated. CT severity score was calculated according to the extent of lesion involvement. In addition, AI based quantification of GGO and consolidation volume were also performed. 123 patients (mean age: 64.43 ? 14.02; 62 males) were included. GGO + consolidation was more frequently revealed in progress-to-severe group whereas pure GGO was more likely to be found in non-severe group. Compared to non-severe group, patients in progress-to-severe group had larger GGO volume (167.33 ? 167.88 cm[SUP]3[/SUP] versus 101.12 ? 127 cm[SUP]3[/SUP], p = 0.013) as well as consolidation volume (40.85 ? 60.4 cm[SUP]3[/SUP] versus 6.63 ? 14.91 cm[SUP]3[/SUP], p < 0.001). Among imaging parameters, consolidation volume had the largest area under curve (AUC) in discriminating non-severe from progress-to-severe group (AUC = 0.796, p < 0.001) and patients with or without critical events (AUC = 0.754, p < 0.001). According to multivariate regression, consolidation volume and age were two strongest predictors for disease progression (hazard ratio: 1.053 and 1.071, p: 0.006 and 0.008) whereas age and diabetes were predictors for unfavorable outcome. Consolidation volume quantified on initial chest CT was the strongest predictor for disease severity progression and larger consolidation volume was associated with unfavorable clinical outcome.
 
Back
Top Bottom